01.09.2024 - By i3 Health
Recently, Genmab and AbbVie announced updated results of the phase 1/2 EPCORE™ NHL-1 clinical trial of epcoritamab (epco) for patients with relapsed/refractory follicular lymphoma. In this interview, Dr. Matthew Hadfield and Dr. Alankrita Taneja of the Oncology Data Advisor Fellows Forum speak with Dr. Tahi Ahmadi, Chief Medical Officer at Genmab, and Dr. Jacqueline Nielsen, Therapeutic Area Head for Hematology at AbbVie, about the significance of these results, the benefits of epcoritamab's subcutaneous administration, management of adverse events, and the future role of epcoritamab in the treatment landscape for follicular lymphoma.